Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT00732186 Withdrawn - Clinical trials for Leukemia, Myeloid, Chronic

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML

NCT ID: NCT00728520 Recruiting - Clinical trials for Acute Myeloid Leukemia

Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The drug that will be used in this study is called Azacitidine. Azacitidine belongs to a group of drugs which may restore normal control in cancer cells by affecting the genes and proteins in the body. Azacitidine is approved by the FDA for the treatment of Myelodysplastic Syndrome (MDS), a pre-leukemic bone marrow disease. The purpose of this study is to find out what effect the drug Azacitidine has on Acute Myeloid Leukemia (AML) in elderly patients.

NCT ID: NCT00727766 Completed - Clinical trials for Leukemia, Myeloid, Acute

Oral Clofarabine for Acute Myeloid Leukemia

Start date: January 2009
Phase: Phase 1
Study type: Interventional

This is a phase I study designed to test the safety of oral clofarabine when given as consolidation therapy to older patients with AML in remission.

NCT ID: NCT00726934 Completed - Sarcoma Clinical Trials

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Start date: September 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if FDA approved food safety guidelines are equivalent to a low bacterial diet (the neutropenic diet) with respect to the acquisition of infections during neutropenia in a sample of pediatric cancer patients.

NCT ID: NCT00725283 Completed - Clinical trials for Leukaemia, Myelocytic, Acute

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

Start date: October 1, 2008
Phase: Phase 1
Study type: Interventional

This study is being done to evaluate the safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-consolidation therapy in adult patients with WT1-positive Acute Myeloid Leukemia in first complete remission. It will also be analyzed to what extent this treatment induces an immune response, specific to the malignancy.

NCT ID: NCT00723099 Completed - Lymphoma Clinical Trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Start date: June 25, 2008
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer. Giving chemotherapy and total-body irradiation (TBI) before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from an unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening.

NCT ID: NCT00720850 Terminated - Clinical trials for Myelodysplastic Syndromes

Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

LENAMAINT
Start date: April 2008
Phase: Phase 2
Study type: Interventional

The hypothesis of this study is that lenalidomide can be an effective drug in preventing relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q after allogeneic HSCT. Due to its immunomodulatory action it might also be able to enhance a T - or NK cell mediated graft versus leukemia (GVL) effects. Nevertheless, one has to keep in mind a possible, yet unknown influence on modulation of clinical GVHD.

NCT ID: NCT00719888 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Start date: November 18, 2005
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease. Giving chemotherapy, such as cyclophosphamide and fludarabine, and TBI before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening.

NCT ID: NCT00719836 Completed - Clinical trials for Myelodysplastic Syndromes

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

Start date: August 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This study consists of two phases: the first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with advanced myeloid malignancies; the second portion of the study is a Phase 2 study to define the efficacy and safety profile of single-agent SB1518 at the recommended dose in subjects with chronic idiopathic myelofibrosis (CIMF).

NCT ID: NCT00718263 Active, not recruiting - Clinical trials for Myelogenous Leukemia, Chronic

Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

PHCHBS-WD4070
Start date: April 2008
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and tolerability of nilotinib after failure of imatinib therapy or imatinib therapy after nilotinib failure.